Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

GENFIT S.A. American Depositary Shares (GNFT)

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/27/2019

Market Cap

216,342,712

Shares Outstanding

49,840,000

Weighted SO

49,834,983

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

CYT --.--%

ERYP --.--%

ELYM --.--%

HCWB --.--%

MOLN --.--%

MNOV --.--%

ANEB --.--%

CSBR --.--%

KROS --.--%

Beta

1.0840

Last Div

0.0000

Range

2.894-6.05

Chg

0.0450

Avg Vol

24732

Mkt Cap

216342712

Exch

NASDAQ

Country

FR

Phone

33 3 20 16 40 00

DCF Diff

10.3262

DCF

-5.1362

Div Yield

0.0000

P/S

5.0423

EV Multiple

-4.5099

P/FV

2.9066

Div Yield %

0.0000

P/E

-4.5215

PEG

0.2170

Payout

0.0000

Current Ratio

2.9396

Quick Ratio

2.9395

Cash Ratio

2.0215

DSO

306.5835

DIO

0.3719

Op Cycle

306.9554

DPO

971.3500

CCC

-664.3946

Gross Margin

0.8992

Op Margin

-1.1227

Pretax Margin

-1.2475

Net Margin

-1.1130

Eff Tax Rate

0.1071

ROA

-0.2500

ROE

-0.6096

ROCE

-0.3241

NI/EBT

0.8922

EBT/EBIT

1.1112

EBIT/Rev

-1.1227

Debt Ratio

0.3771

D/E

0.9695

LT Debt/Cap

0.4601

Total Debt/Cap

0.4923

Int Coverage

-7.7869

CF/Debt

-1.2796

Equity Multi

2.5710

Rec Turnover

1.1905

Pay Turnover

0.3758

Inv Turnover

981.5000

FA Turnover

4.9465

Asset Turnover

0.2246

OCF/Share

-1.6829

FCF/Share

-1.7288

Cash/Share

1.5653

OCF/Sales

-2.1479

FCF/OCF

1.0273

CF Coverage

-1.2796

ST Coverage

-10.5627

CapEx Coverage

-36.6662

Div&CapEx Cov

-36.6662

P/BV

2.9066

P/B

2.9066

P/S

5.0423

P/E

-4.5215

P/FCF

-2.2853

P/OCF

-2.3431

P/CF

-2.3431

PEG

0.2170

P/S

5.0423

EV Multiple

-4.5099

P/FV

2.9066

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Jan 15, 16:10 GENFIT Announces 2024 Financial Calendar   GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Jan 15, 16:10 GENFIT Announces 2024 Financial Calendar   GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Jan 15, 16:10 GENFIT Announces 2024 Financial Calendar   GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Jan 15, 16:10 GENFIT Announces 2024 Financial Calendar   GlobeNewswire Inc. Jan 15, 16:10 GENFIT annonce son calendrier financier pour 2024 GlobeNewswire Inc. Dec 08, 01:55 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) GlobeNewswire Inc. Dec 08, 01:55 GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC) GlobeNewswire Inc. Dec 07, 05:15 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Revenue Product Segmentation